Donepezil, the most widely used drug for treatment of Alzheimer's disease (AD), is an acetylcholinesterase (AChE) inhibitor and thought to improve cognition by stimulating cholinergic neurotransmission. However, no correlation has yet been established between inhibitory role AChE inhibitors their therapeutic effects when in AD patients. The cleavage pathway amyloid precursor protein (APP) inclu...

Introduction. Acute renal failure (ARF) develops in 33% of the patients with rhabdomyolysis. The main etiologic factors are alcoholism, trauma, exercise overexertion, and drugs. In this report we present a rare case of ARF secondary to probably donepezil-induced rhabdomyolysis. Case Presentation. An 84-year-old male patient was admitted to the emergency department with a complaint of generalize...

BACKGROUND/AIM Recent data have indicated that the rs1080985 single nucleotide polymorphism (SNP) of the cytochrome P450 (CYP) 2D6 and the common apolipoprotein E (APOE) gene may affect the response to donepezil in patients with Alzheimer's disease (AD). We investigated this association in Chinese patients with mild-to-moderate AD. METHODS In this prospective cohort study, analyses of CYP2D6 ...

The purpose of this paper is to examine whether oxiracetam and aniracetam are more effective than donepezil and tacrine, two drugs currently used to treat Alzheimer’s disease. Past research suggests that oxiracetam and aniracetam are more therapeutically efficacious than donepezil and tacrine in the treatment of Alzheimer’s disease symptoms (i.e., cognitive deterioration, tolerability, and qual...

AIM The aim of this study was to investigate the metabolism and elimination of donepezil HCl in humans, following the administration of a single 5 mg (liquid) oral dose containing a mixture of unlabelled and 14C-labelled donepezil. METHODS This was an open-label, non-randomized study in healthy male volunteers (n = 8). Characterization of donepezil metabolism and elimination was performed by ...

BACKGROUND Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated with either donepezil 23 mg/d or 10 mg/d and to identi...

Current palliative pharmacotherapy of Alzheimer’s disease based on the cholinergic hypothesisled to the development of four cholinesterase inhibitors. These compounds can bring prolongationof the symptom-free period in some patients. This is the frst report directly comparing donepeziland rivastigmine plasma and brain levels in <span class="font...

Current palliative pharmacotherapy of Alzheimer’s disease based on the cholinergic hypothesisled to the development of four cholinesterase inhibitors. These compounds can bring prolongationof the symptom-free period in some patients. This is the frst report directly comparing donepeziland rivastigmine plasma and brain levels in <span class="font...

BACKGROUND AND OBJECTIVE There are currently no drugs approved to treat vascular dementia (VaD). The objective of this study was to determine if treatment with donepezil, an acetylcholinesterase inhibitor, may provide benefit for VaD patients. METHODS Combined analysis of 2 identical randomized, double-blind, placebo-controlled, 24-week studies involving 1,219 patients enrolled at 109 investi...

Background: No single pharmacologic treatment has proven effective for the symptomatic management of progressive supranuclear palsy. Methods: We report a case of postural instability and falls secondary to PSP of the Parkinson's subtype and initial monotherapy with donepezil 10 mg daily for 3 months followed by a novel investigation of selegiline in combination for 6 additional months. Fall fre...